$ABBV dividend yield has fallen to around 2.6%, its lowest level since 2018, largely because the stock price has climbed faster than its dividend. But a lower yield doesn’t necessarily mean the opportunity is gone.

With a strong drug pipeline and a history of dividend increases, AbbVie could still appeal to people focused on long-term income and growth. I’m curious whether $ABBV can keep rewarding shareholders while maintaining its growth momentum. Would you consider it at these levels?